Marché mondial du traitement des troubles du nerf optique – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

Ces dernières années, le marché du traitement des troubles du nerf optique devrait connaître une croissance rapide au cours de la période de prévision. La rétine et le nerf optique font partie des éléments essentiels de l'œil. La rétine collecte l'image et l'image capturée est transmise au cerveau pour analyse. Les traumatismes, la sclérose en plaques (SEP) et le glaucome affectent le nerf optique. Selon l'Organisation mondiale de la santé (OMS), 2,2 milliards de personnes étaient touchées par une déficience visuelle ou la cécité en 2019. Les cataractes, les erreurs de réfraction non corrigées, l'opacification cornéenne, le glaucome et d'autres affections sont parmi les causes les plus courantes de déficience visuelle.

Français Data Bridge Market Research analyse que le marché du traitement des troubles du nerf optique était évalué à 1,92 milliard USD en 2021 et devrait atteindre 2,73 milliards USD d'ici 2029, enregistrant un TCAC de 4,50 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe Data Bridge Market Research comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

Le deuxième nerf crânien, le nerf optique de l'œil, participe à la transmission des informations sensorielles au cerveau pour la vision. Au cours du développement fœtal, la vésicule optique du prosencéphale se développe en ce nerf. Une perte de la vision peut survenir si le nerf optique ou ses voies vers le cerveau sont endommagés. Le glaucome, l'atrophie du nerf optique, la névrite optique et les drusen de la tête du nerf optique sont des maladies courantes du nerf optique présentes dans le monde entier. La majorité de ces maladies sont traitées de manière symptomatique. Les traitements n'améliorent peut-être pas la vue, mais ils peuvent aider à prévenir la perte de vision à mesure que la maladie progresse.

Portée du rapport et segmentation du marché

Optic Nerve Disorders Treatment Market Dynamics

Drivers

• Increasing prevalence of eye diseases

The rising prevalence of eye diseases is estimated to enhance the growth of the optic nerve disorders treatment market. As per the American Academy of Ophthalmology, approximately 7.32 million people will be diagnosed with primary open-angle glaucoma (POAG) in 2019, with the highest rates among people aged 70 to 79 years old (32%), women (50%), and Hispanics (50 percent ).

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of optic nerve disorders treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Rising number of cases of glaucoma

The surging number of glaucoma and multiple sclerosis (M.S.) cases is anticipated to expand the optic nerve disorders treatment market. Glaucoma is referred to a medical condition which is characterized by a rise in intraocular fluid pressure. The inflammation of the optic nerve causes optic neuritis, while other illnesses are triggered by physical injury to the optic nerve or the development of protein or calcium pockets in the optic nerve.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to the optic nerve disorders treatment market, further estimated to enhance its growth rate.

• High prevalence of multiple sclerosis (M.S.)

The high prevalence of multiple sclerosis (M.S.) is expected to be a major driver for the optic nerve disorders treatment market’s growth. M.S. is an autoimmune disease in which the immune system assaults healthy bodily components, resulting in eyesight loss or decrease in more than half of the cases. As a result, manufacturers are expanding their production capacity in order to develop immunosuppressive medications that improve patients' quality of life. In September 2019, Roche, a Swiss multinational healthcare company, announced the results of clinical studies for Ocrevus, an immunosuppressive medicine, to better understand its impact in relapsing and progressive M.S.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the optic nerve disorders treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the optic nerve disorders treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the optic nerve disorders treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This optic nerve disorders treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the optic nerve disorders treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Optic nerve disorders treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Optic Nerve Disorders Treatment Market

Over the projected period, the optic nerve disorders treatment market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the optic nerve disorders treatment market.

Recent Development

• In August 2020, the U.S. Food and Drug Administration (FDA) approved Enspryng (satralizumab-mwge) for treating neuromyelitis optica spectrum disorder (NMOSD) in adults. Enspryng was given fast track designation, which expedites the development and review of drugs that are intended to treat a serious condition and show promise of meeting an unmet medical need. The drug was also designated as an orphan drug, which provides financial incentives to help and stimulate drug development for rare disorders.

Global Optic Nerve Disorders Treatment Market Scope

The optic nerve disorders treatment market is segmented on the basis of indication, drug class, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Glaucoma
• Optic Neuritis
• Optic Nerve Gliomas
• Optic Nerve Drusen
• Optic Nerve Coloboma
• Optic Atrophy
• Others

Drug Class

• Beta Blockers
• Prostaglandins
• Alpha Adrenergic Agonist
• Carbonic Anhydrase Inhibitors
• Antibiotics
• Corticosteroids
• Others

Diagnosis

• Imaging Tests
  • Magnetic resonance imaging (MRI)
• Ophthalmoscopy
• Eye exams

Dosage form

• Tablets
• Injections
• Solution
• Others

Route of Administration

• Oral
• Topical
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Optic Nerve Disorders Treatment Market Regional Analysis/Insights

The optic nerve disorders treatment market is analysed and market size insights and trends are provided by country, indication, drug class, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the optic nerve disorders treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the optic nerve disorders treatment market because of the presence of major key players and increasing patient population in this region. Additionally, rising healthcare expenditure will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to the increasing number of government initiatives in this region. Also, development of healthcare infrastructure and rising population will further propel the market’s growth rate in this region.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché du traitement des troubles du nerf optique

Le paysage concurrentiel du marché du traitement des troubles du nerf optique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du traitement des troubles du nerf optique.

Certains des principaux acteurs opérant sur le marché du traitement des troubles du nerf optique sont :

• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Novartis SA (Suisse)
• Zydus Cadila (Inde)
• Boehringer Ingelheim International GmbH. (Allemagne)
• Apotex Inc. (Canada)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson (États-Unis)
• Bayer AG (Allemagne)
• Sun Pharmaceutical Industries Ltd. (Inde)
• LEO Pharma A/S (Danemark)
• Les Compagnies de Santé Bausch Inc. (Canada)
• Allergan (Irlande)
• Eli Lilly and Company (États-Unis)
• Aurobindo Pharma (Inde)
• Lupin (Inde)

SKU-54112